ADMA Biologics
Update in progressADMA (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets plasma-derived biologics for immune deficiencies and infectious diseases in the United States. It runs ADMA BioManufacturing and Plasma Collection Centers. Products include BIVIGAM and ASCENIV (IVIG) for primary humoral immunodeficiency, and Nabi-HB for Hepatitis B exposure. It also operates plasma facilities and sells through distributors and wholesalers. Founded 2004, Ramsey, New Jersey.
Company score
- Sentiment
- 0.30
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.11
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.11
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.02
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.16
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMr. Adam S. Grossman
- Founded2004
- Employees640
- Websitewww.admabiologics.com
Identifiers
- ISINUS0008991046
- FIGIBBG002NCK5M5
- CUSIP000899104
- CIK0001368514